Abstract: A device and system for non-invasively measuring wavelength-dependent changes in optical absorption of brain tissue damaged by CTE, TBI, concussion, repetitive trauma, and/or Lou Gehrig’s disease in comparison to signals from healthy normal tissue for a subject in vivo. The brain, tissues, and fluids superficial to the brain are trans-cranially illuminated by light source(s) in low-absorption spectral windows for tissue in the visible and/or near-infrared parts of the spectrum. Optode(s) are disposed at predetermined radial distance(s) from a light output to collect the scattered and/or deflected signal from the surface of the head. The predetermined radial distance from the light output to the optode is correlated with the depth of tissue penetration for the light collected by the optode. A spectrometer and computer analyze the collected light for characteristic optical signatures of the brain tissue damage utilizing the absorbance and/or reflectance and/or transmission spectra generated as a result.

Abstract: A device and system for non-invasively measuring wavelength-dependent changes in optical absorption of brain tissue damaged by CTE, TBI, concussion, repetitive trauma, and/or Lou Gehrig's disease in comparison to signals from healthy normal tissue for a subject in vivo. The brain, tissues, and fluids superficial to the brain are trans-cranially illuminated by light source(s) in low-absorption spectral windows for tissue in the visible and/or near-infrared parts of the spectrum. Optode(s) are disposed at predetermined radial distance(s) from a light output to collect the scattered and/or deflected signal from the surface of the head. The predetermined radial distance from the light output to the optode is correlated with the depth of tissue penetration for the light collected by the optode. A spectrometer and computer analyze the collected light for characteristic optical signatures of the brain tissue damage utilizing the absorbance and/or reflectance and/or transmission spectra generated as a result.

Abstract: A device and system for non-invasively measuring wavelength-dependent changes in optical absorption of brain tissue damaged by CTE, TBI, concussion, repetitive trauma, and/or Lou Gehrig's disease in comparison to signals from healthy normal tissue for a subject in vivo. The brain, tissues, and fluids superficial to the brain are trans-cranially illuminated by light source(s) in low-absorption spectral windows for tissue in the visible and/or near-infrared parts of the spectrum. Optode(s) are disposed at predetermined radial distance(s) from a light output to collect the scattered and/or deflected signal from the surface of the head. The predetermined radial distance from the light output to the optode is correlated with the depth of tissue penetration for the light collected by the optode. A spectrometer and computer analyze the collected light for characteristic optical signatures of the brain tissue damage utilizing the absorbance and/or reflectance and/or transmission spectra generated as a result.

Abstract: A daily nutritional or dietary supplement composition that strengthens and promotes retinal health through the prevention, stabilization, reversal and/or treatment of visual acuity loss by reducing the risk of developing late stage or advanced age-related macular degeneration in persons with early age-related macular degeneration. The ingredients of the daily nutritional or dietary supplement composition include vitamin C, vitamin E, lutein, zinc and copper. The ingredients are preferably provided in a tablet form suitable for oral ingestion.

Abstract: Protein complexes are provided comprising at least one interacting pair of proteins. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes, and in treating and/or preventing diseases and disorders associated with the protein complexes and/or their constituent interacting members.

Abstract: Protein complexes are provided comprising at least one interacting pair of proteins. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes, and in treating and/or preventing diseases and disorders associated with the protein complexes and/or their constituent interacting members.

Abstract: The present invention generally relates to methods and compositions for treating neurological disorders and diseases. In addition, methods for selecting therapeutic agents useful for treating neurological disorders and diseases are provided.

Abstract: The invention provides methods of treating, preventing, delaying the onset, slowing the progression, or reversing the symptoms of Alzheimer's disease and other neurodegenerative diseases characterized by the accumulation of amyloid plaques comprising the A?42 peptide. The invention also provides compounds that reduce the production or secretion of the A?42-peptide by cells, and pharmaceutical compositions comprising such compounds, for the treatment of neurodegenerative diseases characterized by the accumulation of amyloid plaques comprising the A?42 peptide.

Abstract: Small organic molecules capable of effecting a “pharmacological trabeculocanalotomy” in an eye by means of reducing juxtacanalicular meshwork as a barrier to outflow of aqueous. The small organic molecules increase Gelatinase A activity in ocular cells by increasing cell membrane expression of membrane-type matrix metalloproteinases (MT-MMPs) to increase aqueous outflow as a treatment for primary open angle glaucoma.

Abstract: Novel PN7718 protein and nucleic acids encoding PN7718 are provided. PN7718-containing protein complexes formed by PN7718 and a PN7718-interacting protein (e.g., cyclophilin C) are also provided. Cyclophilin C and PN7718 may be involved in common biological processes such as intracellular calcium signaling, beta-amyloid formation, T-cell receptor and IgE receptor signaling pathways, and protein folding and degradation. Thus, the protein complexes as well as PN7718 can be used in screening assays to select modulators of PN7718 and the protein complexes formed by PN7718 and cyclophilin C. The identified modulators can be useful in modulating the functions and activities of PN7718 and protein complexes containing PN7718, and in treating and preventing autoimmune diseases, neurological diseases and cardiovascular disorders.

Abstract: Protein complexes are provided comprising at least one interacting pair of proteins. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes, and in treating and/or preventing diseases and disorders associated with the protein complexes and/or their constituent interacting members.

Abstract: Protein complexes are provided comprising at least one interacting pair of proteins. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes, and in treating and/or preventing diseases and disorders associated with the protein complexes and/or their constituent interacting members.

Abstract: Chemical erosion controlled release drug delivery systems are provided that allow controlled release of sustained concentrations of therapeutic agents within a treated area for a prolonged period of time. The favorable solubility characteristics of the chemical erosion controlled release drug delivery systems are controlled through the hydrophobicity and load level of pharmaceutically active agent or drug. Such controlled solubility characteristics allow for manipulation of the drug release rates depending on the particular therapeutic use and the particular needs of the patient.

Abstract: Protein complexes are provided comprising MAP17 and SCAMP2. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with MAP17 and SCAMP2. In addition, methods for detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Abstract: The present invention generally relates to methods and compositions for treating neurological disorders and diseases. In addition, methods for selecting therapeutic agents useful for treating neurological disorders and diseases are provided.

Abstract: Protein complexes are provided comprising at least one interacting pair of proteins. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes, and in treating and/or preventing diseases and disorders associated with the protein complexes and/or their constituent interacting members.

Abstract: Small organic molecules capable of effecting a “pharmacological trabeculocanalotomy” in an eye by means of reducing juxtacanalicular meshwork as a barrier to outflow of aqueous. The small organic molecules increase Gelatinase A activity in ocular cells by increasing cell membrane expression of membrane-type matrix metalloproteinases (MT-MMPs) to increase aqueous outflow as a treatment for primary open angle glaucoma.

Abstract: A nutritional or dietary supplement composition that strengthens and promotes retinal health through the prevention, stabilization, reversal and/or treatment of visual acuity loss by reducing the risk of developing late stage or advanced age-related macular degeneration in persons with early age-related macular degeneration. The nutritional or dietary supplement composition may likewise reduce the risk of vision loss associated with the development of cataracts. The essential ingredients of the nutritional or dietary supplement composition are vitamin C, vitamin E, beta-carotene, zinc and copper. The essential ingredients are preferably provided in a tablet form suitable for oral ingestion. Preferably the composition is taken in the form of one or two tablets taken twice daily.

Abstract: A nutritional or dietary supplement composition that strengthens and promotes retinal health through the prevention, stabilization, reversal and/or treatment of visual acuity loss by reducing the risk of developing late stage or advanced age-related macular degeneration in persons with early age-related macular degeneration. The nutritional or dietary supplement composition may likewise reduce the risk of vision loss associated with the development of cataracts. The essential ingredients of the nutritional or dietary supplement composition are vitamin C, vitamin E, beta-carotene, zinc and copper. The essential ingredients are preferably provided in a tablet form suitable for oral ingestion. Preferably the composition is taken in the form of one or two tablets taken twice daily.

Abstract: Protein complexes are provided comprising APOA2 and one or more APOA2-interacting proteins. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with APOA2 and its interacting partners. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.